TACE聯合RFA治療原發性肝癌中長期生存率研究
論著
作者：姚征等
[摘要] 目的 探討TACE聯合RFA對原發性肝癌對患者長期生存率的影響。 方法 選取2009年6月～2014年6月於我院進行治療的100例中晚期原發性肝癌患者。按照隨機數字表法將其分為射頻治療組（RFA，50例）和聯合治療組（TACE+RFA，50例）。其中，射頻治療組患者單純進行RFA治療；聯合治療組患者采取RFA和TACE結合聯合治療。隨訪時間為12～50個月，比較兩組患者的長期療效及生存狀況。 結果 通過分析對比兩組患者治療後遠期生存狀況發現，射頻治療組患者生存期為1～60個月，聯合治療組患者生存期為2～89個月。1年生存率聯合治療組顯著高於射頻治療組（P
[關鍵字] 經導管動脈內化療栓塞；射頻消融治療；原發性肝癌；長期；生存率
[中圖分類號] R735.7 [文獻標識碼] A [文章編號] 1673-9701（2015）22-0001-04
Research on the long-term survival of primary liver cancer of TACE combined with RFA
YAO Zheng1 CHEN Yutang1 CHEN Bo2
1.Department of Invasive Technology， Zhejiang Cancer Hospital， Hangzhou 310022， China； 2.Department of Pathology， Zhejiang Cancer Hospital， Hangzhou 310022， China
[Abstract] Objective To explore the long-term survival of primary liver cancer of TACE combined with RFA. Methods A total of 100 cases were selected from June 2009 to June 2014 in our hospital treated with advanced hepatocellular carcinoma， according to a random number table method， they were randomly divided into treatment group radiofrequency（RFA， 50 patients）， and combined treatment group （TACE+RFA， 50 patients）. Among them， the RF-treated patients were treated with RFA alone； the combined treatment group were taken RFA and TACE combined with combination therapy. Follow-up for 12 to 50 months， the long-term efficacy and survival of the two groups of patients were compared. Results By analyzing and comparing two groups of patients after treatment， long-term survival of discovery， survival radiofrequency of treatment group was 1 to 60 months， the survival of patients combined treatment group was 2 to 89 months. 1-year survival rate of the combined treatment group was significantly higher than the radiofrequency treatment group（P
[Key words] Transcatheter arterial chemoembolization；Radiofrequency ablation；Hepatocellular carcinoma；Long-term；Survival rate
肝髒腫瘤有良性腫瘤與惡性腫瘤兩種，其中以惡性腫瘤最為普遍，而原發性肝癌（HCC）的常見度最高[1]。近年來，其發病率有顯著增高的趨勢，且發病具有隱匿性與迅速性，對多數不能按時進行體檢的人來說，很難及時發現；一經發現已至中晚期而失去了手術治療的最佳時機。目前能夠及時接受手術治療的患者僅為20%，且預後不良情況較為普遍，患者生存率也並不高[2-3]。肝癌的非手術治療方法種類較多，其中經導管肝動脈化療藥物栓塞術（TACE）、射頻消融術（RFA）及TACE 聯合RFA治療是比較主要的三種治療方法[4]。本研究通過比較RFA與TACE聯合RFA治療兩種方案的長期治療效果，幫助醫師提高未來治療方法選擇上的認識，也有助於患者治療後生存率以及生存質量的改善提高。現報道如下。